PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Toripalimab

Drugs in development · updated 30 October 2026

Toripalimab: clinical trials and development status

Other names and codes: JS001, Loqtorzi

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 19 September 2024

As of 30 October 2026 Toripalimab is in 271 active clinical trials (recruiting or ongoing, phases I–III) for 60 diseases. The most advanced phase is III.

271Active trials
IIIMost advanced phase
60Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Toripalimab and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 60 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Nasopharyngeal CarcinomaIII29NCT06712888
Non-small-cell lung carcinomaIII19NCT07672223
Head and neck squamous cell carcinomaIII17NCT07371897
Triple-negative breast neoplasmIII14NCT07111832
Breast neoplasmIII12NCT06977893
Esophageal squamous cell carcinomaIII11NCT07246330
Bladder neoplasmII–III10NCT07756008
Renal cell carcinomaIII8NCT05738694
Lung small cell carcinomaIII7NCT06095583
Transitional cell carcinomaIII7NCT06592326
Hepatocellular carcinomaIII6NCT07823348
Stomach neoplasmII–III5NCT05980481
Esophageal neoplasmIII3NCT07177794
CholangiocarcinomaIII2NCT05342194
Hodgkin lymphomaIII1NCT06170489
Colorectal neoplasmII9NCT07896681
Head and neck neoplasmsII7NCT07214987
NeoplasmII7NCT07879469
Biliary tract neoplasmII4NCT07159217
MetastasisII4NCT07423078
Laryngeal neoplasmII3NCT07209189
Oropharyngeal NeoplasmsII3NCT07209189
Pancreatic neoplasmII3NCT07469956
SarcomaII3NCT04589741
Squamous cell carcinomaII3NCT07214987
Turcot syndromeII3NCT06903858
Uterine cervix neoplasmII3NCT07363330
CarcinomaII2NCT07855965
Colonic neoplasmII2NCT07896681
Hypopharyngeal NeoplasmsII2NCT06039631

Everything on Toripalimab

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch